RIO DE JANEIRO, BRAZIL - The third and last phase of the clinical trials of the Cuban vaccine candidate Soberana 02 against the coronavirus concludes this Wednesday, May 26, when all the volunteers participating in the tests are expected to have completed the immunization scheme.
Soberana 02 and Abdala -which already completed its phase 3 at the beginning of May- are the two most advanced of the five formulas Cuba is developing against Covid-19. If these studies prove their effectiveness, they will become the first vaccines developed in Latin America.
Confirmation of efficacy would also enable the island's health . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here